首页 › 滤泡性淋巴瘤 › 田纳西州 › Nashville
Nashville TN 滤泡性淋巴瘤临床试验
18项针对 滤泡性淋巴瘤的研究正在 Nashville及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
招募中1/2 期
- Tennessee Oncology, Pllc Nashville, Nashville
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
招募中1 期
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
招募中2/3 期
- SCRI Oncology Partners ( Site 7000), Nashville
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
招募中1/2 期
- SCRI Oncology Partners ( Site 0100), Nashville
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
招募中1 期
- SCRI Oncology Partners, Nashville
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
招募中1 期
- Sarah Cannon Research Institute, Nashville
- Vanderbilt University Medical Center, Nashville
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
招募中3 期
- Research Site, Nashville
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
招募中2 期
- Research Site, Nashville
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
招募中3 期
- Tennessee Oncology, Nashville
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
招募中3 期
- Vanderbilt University Medical Center, Nashville
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
招募中1 期
- Vanderbilt University/Ingram Cancer Center, Nashville
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
招募中3 期
- Vanderbilt-Ingram Cancer Center, Nashville
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
招募中1/2 期
- Vanderbilt University Medical Center, Nashville
Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder
招募中2 期
- Vanderbilt University Medical Center, Nashville
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
招募中1/2 期
- TriStar BMT, Nashville
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
招募中1 期
- Tennessee Oncology, Nashville
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
招募中1 期
- Tennessee Oncology, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中观察性研究
- Massive Bio SYNERGY-AI site, Nashville
其他城市的 滤泡性淋巴瘤试验
- New York City, NY24 项研究
- Milwaukee, WI19 项研究
- Houston, TX18 项研究
- Boston, MA17 项研究
- Baldwin Park, CA16 项研究
- Seattle, WA15 项研究
- Durham, NC15 项研究
- Columbus, OH13 项研究
- Salt Lake City, UT13 项研究
- Chicago, IL12 项研究
- San Antonio, TX12 项研究
- Philadelphia, PA12 项研究
Nashville的其他研究
- 非小细胞肺癌97 项研究
- 乳腺癌81 项研究
- 转移性癌症70 项研究
- 结直肠癌69 项研究
- 癌症（所有类型）65 项研究
- 卵巢癌49 项研究
- 前列腺癌43 项研究
- 肺癌40 项研究
- 头颈鳞状细胞癌39 项研究
- 胰腺癌39 项研究
- 子宫内膜癌38 项研究
- 黑色素瘤33 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。